TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Senzime AB ( (SE:SEZI) ) has shared an announcement.
Senzime AB has secured a significant contract with the U.S. Department of Defense to supply its TetraGraph system to Walter Reed National Military Medical Center, marking a major commercial milestone. This partnership highlights Senzime’s commitment to patient safety and its strong market position, as the TetraGraph system is widely used in operating rooms globally to ensure accurate dosing of neuromuscular blocking agents, enhancing patient recovery post-surgery.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company based in Uppsala, Sweden, specializing in precision-based monitoring systems that enhance perioperative patient safety. Established in 1999, the company is known for its TetraGraph system, which accurately monitors neuromuscular transmission during surgery. Senzime is publicly traded on the Nasdaq Stockholm Main Market and cross-trades on the US OTCQX Market.
Average Trading Volume: 504,323
Technical Sentiment Signal: Sell
Current Market Cap: SEK974.7M
Find detailed analytics on SEZI stock on TipRanks’ Stock Analysis page.